Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells

2019 ◽  
Vol 46 (5) ◽  
pp. 4809-4816 ◽  
Author(s):  
Amin Soltani ◽  
Samira Torki ◽  
Milad Sabzevary Ghahfarokhi ◽  
Mohammad Saied Jami ◽  
Mahdi Ghatrehsamani
BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wangming Zhang ◽  
Shuang Yang ◽  
Jinhe Liu ◽  
Linchun Bao ◽  
He Lu ◽  
...  

Abstract Background The high expression of BLM (Bloom syndrome) helicase in tumors involves its strong association with cell expansion. Bisbenzylisoquinoline alkaloids own an antitumor property and have developed as candidates for anticancer drugs. This paper aimed to screen potential antiproliferative small molecules from 12 small molecules (the derivatives of bisbenzylisoquinoline alkaloids tetrandrine and fangchinoline) by targeting BLM642–1290 helicase. Then we explore the inhibitory mechanism of those small molecules on proliferation of MDA-MB-435 breast cancer cells. Methods Fluorescence polarization technique was used to screen small molecules which inhibited the DNA binding and unwinding of BLM642–1290 helicase. The effects of positive small molecules on the ATPase and conformation of BLM642–1290 helicase were studied by the malachite green-phosphate ammonium molybdate colorimetry and ultraviolet spectral scanning, respectively. The effects of positive small molecules on growth of MDA-MB-435 cells were studied by MTT method, colony formation and cell counting method. The mRNA and protein levels of BLM helicase in the MDA-MB-435 cells after positive small molecule treatments were examined by RT-PCR and ELISA, respectively. Results The compound HJNO (a tetrandrine derivative) was screened out which inhibited the DNA binding, unwinding and ATPase of BLM642–1290 helicase. That HJNO could bind BLM642–1290helicase to change its conformationcontribute to inhibiting the DNA binding, ATPase and DNA unwinding of BLM642–1290 helicase. In addition, HJNO showed its inhibiting the growth of MDA-MB-435 cells. The values of IC50 after drug treatments for 24 h, 48 h and 72 h were 19.9 μmol/L, 4.1 μmol/L and 10.9 μmol/L, respectively. The mRNA and protein levels of BLM helicase in MDA-MB-435 cells increased after HJNO treatment. Those showed a significant difference (P < 0.05) compared with negative control when the concentrations of HJNO were 5 μmol/L and 10 μmol/L, which might contribute to HJNO inhibiting the DNA binding, ATPase and DNA unwinding of BLM helicase. Conclusion The small molecule HJNO was screened out by targeting BLM642–1290 helicase. And it showed an inhibition on MDA-MB-435 breast cancer cells expansion.


2015 ◽  
Vol 7 (7) ◽  
pp. 792-800 ◽  
Author(s):  
Stephanie Lemmo Ham ◽  
Samila Nasrollahi ◽  
Kush N. Shah ◽  
Andrew Soltisz ◽  
Sailaja Paruchuri ◽  
...  

A high throughput screening technology enables identifying natural compounds, phytochemicals, that potently inhibit migration of metastatic breast cancer cells.


2020 ◽  
Vol 02 (01) ◽  
pp. 63-75
Author(s):  
Debasray Saha ◽  
Neeraj Vaishnav ◽  
Zubiya Ahsan ◽  
Nisha Rani ◽  
Runjhun Mathur ◽  
...  

RSC Advances ◽  
2018 ◽  
Vol 8 (61) ◽  
pp. 34773-34782 ◽  
Author(s):  
Adriana Guadalupe Perez-Ruiz ◽  
Adriana Ganem ◽  
Ivonne María Olivares-Corichi ◽  
José Rubén García-Sánchez

Natural compounds such as (−)-epicatechin show a variety of biological properties including anticancer activity.


2008 ◽  
Vol 417 (1) ◽  
pp. e5-e7 ◽  
Author(s):  
Christian Peifer ◽  
Dario R. Alessi

Tamoxifen is one of the most prescribed anti-breast-cancer drugs, but tumours becoming resistant hinder its efficacy in the clinic. There is therefore great interest in developing strategies to reduce resistance and sensitize breast cancer cells to tamoxifen. A groundbreaking study by Iorns et al. published in this issue of the Biochemical Journal suggests that a signal transduction pathway controlled by PDK1 (phosphoinositide-dependent kinase 1) plays a crucial role in regulating the sensitivity of breast cancer cells to tamoxifen. The implications of this study are that PDK1 or PI3K (phosphoinositide 3-kinase), Akt (also known as protein kinase B), S6K (S6 kinase) and mTOR (mammalian target of rapamycin) inhibitors, already being developed for cancer therapy, are likely to have additional utility in sensitizing breast tumours to tamoxifen. In this commentary we also discuss the possibility that inhibiting the PDK1 pathway may help overcome acquired resistance to other anti-cancer treatments.


Sign in / Sign up

Export Citation Format

Share Document